Skip to main content
. 2018 Jan 12;9(11):9741–9750. doi: 10.18632/oncotarget.24188

Figure 4. Progression free survival (PFS) according to ERBB2 mutation or amplification therapy with exclusion of breast or oesogastric adenocarcinoma.

Figure 4

Survival curves were computed with Kaplan Meyer estimation and compared with an unstratified log-rank test.